<DOC>
	<DOCNO>NCT00699543</DOCNO>
	<brief_summary>Objectives : To evaluate clinical efficacy , angiographic outcome , safety new paclitaxel-eluting coronary stent ( CoroflexTM Please , B Braun , Germany ) , compare another paclitaxel-eluting coronary stent system ( TaxusTM , Boston Scientific , USA ) treatment coronary stenosis . Study Design : Prospective , open label , 2 : 1 randomize multi-center trial . Patients randomize accord type drug elute stent ( CoroflexTM Please vs. TaxusTM ) . Randomization also stratify per hospital presence DM presence long lesion ( lesion length &gt; 28mm ) Patient Enrollment :915 patient enrol 13 center Korea . Patient Follow-Up : Clinical follow-up occur 1 , 4 , 9 , 12 month 2 , 3years intervention . Investigator designee may conduct follow-up telephone contact office visit . Primary Endpoint : Clinically drive Target vessel Revascularization ( TVR ) 9 month . Secondary Endpoints : A . Clinical safety efficacy end point 1 . Major Cardiac Adverse Events ( MACE ; All Death , cardiac death , Myocardial infarction ( Q-wave non-Q wave ) , TVR ) 2 . Target Vessel Failure ( TVF ; cardiovascular death , myocardial infarction , clinically drive TVR ) 3 . Stent thrombosis B . Angiographic efficacy end point 1. in-stent binary restenosis QCA 2. in-stent in-lesion late loss QCA 3. in-stent in-lesion MLD percentage diameter stenosis QCA immediately index procedure 9 month follow-up</brief_summary>
	<brief_title>The Efficacies The New Paclitaxel-Eluting CoroflexTM Please Stent Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria General Inclusion Criteria 1 . Subject must least 18 year age . 2 . Subject able verbally confirm understandings risk , benefit treatment alternative receive CoroflexTM Please stent he/she his/her legally authorize representative provide write informed consent prior study related procedure . 3 . Subject must coronary artery stenosis ( &gt; 50 % visual estimate ) evidence myocardial ischemia ( e.g. , stable , unstable angina , myocardial infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia . ) Subject must significant coronary artery stenosis ( &gt; 70 % visual estimate ) Angiographic Inclusion Criteria 1 . Target lesion ( ) must locate native coronary artery visually estimate diameter ≥ 2.5 mm ≤ 4.0 mm . 2 . Target lesion ( ) must amenable percutaneous coronary intervention Exclusion Criteria General Exclusion Criteria 1 . The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel Ticlopidine Paclitaxel Stainless steel Contrast medium ( * ) ( * ) Patients documented sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . 2 . Systemic ( intravenous ) Paclitaxel use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis know coagulopathy ( include heparin induce thrombocytopenia ) , refuse blood transfusion . 5 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 6 . An elective surgical procedure plan would necessitate interruption thienopyridines first 6 month post enrollment . 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 9 . Patients LVEF &lt; 25 % cardiogenic shock 10 . Patients acute ST elevation myocardial infarction require primary PCI 11 . Patients acute ST elevation myocardial infarction within 48hrs 12 . Creatinine level ≥ 3.0mg/dL dependence dialysis . Angiographic Exclusion Criteria 1 . Patients significant leave main stem stenosis require revascularization therapy 2 . Patients 's target lesion instent restenosis stented segment drugeluting stent bare metal stent 3 . Target lesion bifurcate disease require side branch stenting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>